A source of widespread confusion is the entrenched belief that introducing interim analyses “costs” alpha; that is, the assumption that interim adaptations erode the available alpha and require the sponsor to “pay a penalty.” This notion also leads to the myth that just the action of “looking at data” at an interim analysis is bad and costs alpha.

Regression-to-the-mean offers critical insights for drug development, like sports statistics, emphasizing the importance of understanding data variability across multiple levels of inference.

Understanding DSMBs is pivotal in ensuring trial integrity, safety, and success.

A discussion on the intricacies of implementing adaptive clinical trials, their operational processes, and how Berry ensures timely execution.

Explore the intricacies of the AWARD-5 trial for Eli Lilly's dulaglutide, from complex trial design to the transformation of pharmaceutical development timelines.

Explore how adaptive platform trials like I-SPY2 and GBM AGILE are revolutionizing clinical research to accelerate drug development.